Catheter-Associated Urinary Tract Infections Treatment Market

Market Overview

Catheter-associated urinary tract infections, abbreviated as CAUTIs, are the common hospital acquired infections. The infection can be associated with any part of the urinary system. If catheter-associated urinary tract infections treatment is delayed, then the infection may get severe and involve kidney infection.

The associated complications could be catheter encrustation, pyelonephritis, bladder stones, endotoxic shock and septicaemia. CAUTIs can be triggered both by bacterial and yeasts.

All the types of catheter whether made up of silicone, latex or any other polymer are prone to infections.  

Catheter-associated urinary tract infections treatment market has been affected by COVID-19 pandemic in terms of delay of projects in various countries. The supply chain constraints, jammed logistics due to lockdowns and other regulatory restrictions have impacted the global catheter-associated urinary tract infections treatment market.

General shift in priority of attention from catheter-associated urinary tract infections treatment to COVID-19 has also been observed.

Catheter-Associated Urinary Tract Infections Treatment Market: Drivers and Restraints

Increasing number of hospitalization for chronic diseases is generally associated with catheterization which will be an important driver for the global catheter-associated urinary tract infections treatment market.

Growing geriatric population worldwide who have a weak immune system hence are more susceptible to urinary tract infections will increase the target customers base for the use of catheter can also be attributed to the growing global catheter-associated urinary tract infections treatment market.

Lack of sanitary amenities in the healthcare facilities in the developing countries can lead to increase in the infections resulting further driving up the global catheter-associated urinary tract infections treatment market.

Majority of people who contact infection present with fever alone which could delay the catheter-associated urinary tract infections treatment and hence hamper the growth of the global catheter-associated urinary tract infections treatment market.  

Catheter-Associated Urinary Tract Infections Treatment Market: Overview 

The global catheter-associated urinary tract infections treatment market is expected to witness a robust growth as out of all the urinary tract infections CAUTIs constitute around 80% and urinary tract infections are among the most commonly acquired infections from the hospitals.

Based on indication type Cystitis segment can be pitched to witness major growth in the global catheter-associated urinary tract infections treatment market as cystitis is the most common type of urinary tract infection.

Based on the distribution channel type the hospital pharmacies can be expected to register fastest growth in the global catheter-associated urinary tract infections treatment market because often CAUTIs will be treated in the hospital when the patient is hospitalized.  

Catheter-Associated Urinary Tract Infections Treatment Market: Region-wise Outlook 

North America can be estimated to be the major market in the global catheter-associated urinary tract infections treatment market for as there are reports stating that around 13 million populations in the USA is suffering from urinary incontinence per year. 

Growing geriatric population in the Europe coupled with almost 20% suffering from urinary tract infection can be the reason for growth of the global catheter-associated urinary tract infections treatment market in this region.

The increasing incidence of urinary tract infections in the developing countries can be estimated to lead the growth of the global catheter-associated urinary tract infections treatment market in the South Asia East Asia and Africa.

Catheter-Associated Urinary Tract Infections Treatment Market: Key Players 

The key players operating in the global catheter-associated urinary tract infections treatment market are

• GlaxoSmithKline
• Pfizer
• Cipla
• Bayer
• Johnson & Johnson
• Roche
• Novartis
• Boehringer Ingelheim
• AstraZeneca
• Shionogi

The research report presents a comprehensive assessment of the market and contains thoughtful insights facts historical data and statistically supported and industry-validated market data.

It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies application and industry.

The report covers exhaust analysis on: 

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Indication
• Value Chain

Regional analysis includes:

• North America (U.S. Canada)
• Latin America (Mexico. Brazil)
• Europe (Germany U.K France Italy Spain)
• South Asia (India ASEAN Countries)
• East Asia (Japan China & South Korea)
• Oceania (Australia & New Zealand)
• Middle East and Africa (GCC Countries South Africa Northern Africa)

The report is a compilation of first-hand information qualitative and quantitative assessment by industry analysts inputs from industry experts and industry participants across the value chain.

The report provides in-depth analysis of parent market trends macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

• Detailed overview of parent market
• Changing market dynamics in the industry
• In-depth market segmentation
• Historical current and projected market size in terms of volume and value
• Recent industry trends and developments
• Competitive landscape
• Strategies of key players and products offered
• Potential and niche segments geographical regions exhibiting promising growth
• A neutral perspective on market performance
• Must-have information for market players to sustain and enhance their market footprint